Daisy Robinton
Robinton co-founded Oviva to develop drugs that preserve ovarian function and extend women’s healthspan. Its lead program targets ovarian response, but clinical benefit has not been shown.
Profile
Molecular biologist and co-founder of Oviva Therapeutics, where she helped build a program focused on ovarian aging, reproductive longevity, and women’s health before Oviva joined Granata Bio.
Role
entrepreneurhigh confidence
She co-founded Oviva Therapeutics, an operating venture developing AMH-based therapies to improve ovarian function, extend female healthspan, and ultimately delay menopause. Building that company is the clearest demonstrated channel of her longevity contribution.
Dimension breakdown
This score rates longevity commitment only. The role tags above — scientist, investor, and the rest — say what this person is; we don't score those separately.
Future vision
7.0/ 10
Robinton has articulated a clear, ambitious, and therapeutically grounded vision: delaying menopause by preserving ovarian function to extend women’s healthspan. She identifies a concrete destination, a near-term drug-development pathway, and broader health benefits, but the evidence supports an organ-specific vision rather than a comprehensive strategy for ending aging or dramatically extending human lifespan.
medium confidence
Scientific impact
3.0/ 10
Scientific impact is applicable, but the evidence demonstrates limited realized influence. Robinton co-authored two independent, peer-reviewed longevity papers and helped develop an ovarian-aging therapeutic program, yet neither paper is shown to be foundational or heavily cited, and no clinical validation is provided. The Oviva program appears translationally promising but remains supported mainly by company claims and an acquisition rather than demonstrated scientific or clinical outcomes.
low confidence
Capital deployed
N/A
The evidence establishes scientific and operating involvement in longevity biotechnology, including Oviva Therapeutics, but does not show that Robinton personally deployed capital. Founder activity alone cannot be treated as investment or philanthropy without specific evidence.
No public investment, donation, or other capital-deployment activity is evidenced for Daisy Robinton.
high confidence
Strategic taste
6.0/ 10
Robinton made a coherent, relatively early company-building bet that ovarian aging is both a tractable therapeutic target and a driver of female healthspan beyond fertility. Oviva and OVI-586 demonstrate thesis-to-program alignment, and the transition to Granata Bio offers a plausible continuation path. However, the evidence does not establish clinical validation, field-level influence, a strong counterfactual case, or that Robinton uniquely opened this path.
medium confidence
Field creation
6.0/ 10
Robinton co-founded a biotechnology company that established a concrete therapeutic program around ovarian aging and reproductive longevity, helping make an underdeveloped longevity area more legible. Independent sources corroborate Oviva Therapeutics' existence and her association with it, but the evidence does not show that she created a broader field-wide category, coalition, protocol, or funding path with demonstrated uptake by others.
medium confidence
Bravery and conviction
2.0/ 10
Robinton publicly championed an ambitious and unconventional therapeutic program targeting ovarian aging, but the supplied evidence does not establish career sacrifice, substantial personal risk, persistence under serious criticism, or self-experimentation. Founding the company and articulating its bold vision provide a limited signal of conviction, not strong evidence of rubric-defined bravery.
medium confidence
Multiplier effect
4.0/ 10
Robinton shows credible but modest multiplier effects through building Oviva around ovarian aging, helping legitimize reproductive longevity as a biotechnology focus, and positioning its program to continue through Granata Bio. However, the evidence does not quantify talent recruitment, capital attracted, policy influence, collaborations generated, or follow-on ventures.
medium confidence
Vision
Destination
Robinton envisions a not-too-distant future—maybe before she reaches menopause herself—in which women will have therapeutic interventions that allow their ovaries to keep working for longer, helping maintain the skin and hair and mood and health and maybe even the sex life of their younger years.
For me, the pie in the sky is really choosing when to have the sun set on your ovaries,” she says.
“I see it very much akin to how the contraceptive pill really changed the game for women in the ’70s,” Robinton says.
From there, Robinton says, Oviva can eventually tackle the bigger goal: delaying menopause.
Path
No canonical quotes yet.
Strategy
Develop therapeutics that preserve ovarian function to extend reproductive longevity and female healthspan.
Robinton’s strategy centers on company-building around ovarian aging as an intervention point for extending women’s healthspan [S1]. Oviva’s therapeutic thesis treats declining ovarian function as a contributor to adverse health outcomes rather than solely a fertility issue [S1]. The program targets causal biology underlying ovarian aging, with OVI-586 advancing a biologically grounded approach to improving ovarian response in patients with diminished ovarian reserve [S1]. Oviva’s transition into Granata Bio provides a path to continue the program in assisted reproductive technology and explore applications beyond IVF [S1]. No evidence establishes an investment portfolio, donation strategy, geographic preference, risk appetite, or defined time horizon.
UnknownUnknownOvarian AgingReproductive LongevityWomen’S HealthFertility TherapeuticsFemale Healthspan
Notable bets
Portfolio
Investments
No public rows yet.
Donations
No public rows yet.
Organizations founded
Scientific output
h-index-
Citations-
Papers0
Trials0
Belief evolution
Self-experimentation
Connections
Companies
Collaborators and lineage
Criticisms